We focus on appetite control, metabolic balance, and sustainable fat loss through customized medication dosing, nutrition, and lifestyle guidance
It was approved in the UK in 2023 for weight management in adults with: BMI 30 kg/m (obesity), or BMI 27 kg/m (overweight) with at least one weight-related condition The medication works in several ways: Reduces hunger signals by acting on the brains appetite control centre Slows stomach emptying , creating longer-lasting fullness after meals Reduces food cravings , particularly for ultra-processed foods Clinical trials show that people taking Wegovy lose an average of 15% of their body weight after 68 weeks, compared to 2.4% with placebo
Environmental Tobacco Smoke and Cardiovascular Disease
Their starting dose and available dose strengths are similar, while their maintenance-dose guidance differs
GluN2D N-methyl-d-aspartate receptor subunit contribution to the stimulation of brain activity and gamma oscillations by ketamine: implications for schizophrenia